---
layout: default
title: Abacavir
parent: 僅模型預測 (L5)
nav_order: 11
evidence_level: L5
indication_count: 3
---

# Abacavir
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ABACAVIR: Drug Repurposing Evaluation — Pending Prediction Data

## One-Sentence Summary

ABACAVIR is a nucleoside reverse transcriptase inhibitor (NRTI) widely used in the treatment of HIV/AIDS.
The TxGNN model has **not yet generated any predicted new indications** for this drug,
and the current Evidence Pack contains **no clinical trial or literature evidence** for repurposing candidates.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not listed in current data (known use: HIV-1 infection) |
| Predicted New Indication | — None predicted |
| TxGNN Prediction Score | — Not available |
| Evidence Level | L5 (No prediction or supporting studies) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

There is currently **no TxGNN prediction to evaluate**. The `predicted_indications` array in the Evidence Pack is empty, meaning the model has not identified any repurposing candidates for ABACAVIR at this time.

ABACAVIR is a well-established nucleoside analogue reverse transcriptase inhibitor (NRTI). It is intracellularly phosphorylated to its active metabolite carbovir triphosphate, which competes with the natural substrate dGTP and incorporates into viral DNA, causing chain termination. Detailed mechanism of action data was not available in the Evidence Pack (flagged as data gap DG002); however, ABACAVIR's antiviral mechanism is highly specific to HIV-1 reverse transcriptase, which may limit its applicability to non-viral disease indications without further computational or experimental evidence.

Until the TxGNN model produces a scored prediction for a new indication, no mechanistic plausibility assessment can be conducted.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for any predicted repurposing indication.

---

## Literature Evidence

Currently no related literature available for any predicted repurposing indication.

---

## Taiwan Market Information

ABACAVIR currently holds **no TFDA marketing authorizations** in Taiwan. There are no licensed products to report.

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> Note: Package insert warning/contraindication data could not be retrieved (data gap DG001, severity: **Blocking**). No drug-drug interaction records were found in the queried databases. This data gap must be resolved before any safety initial assessment (S1) can proceed.

---

## Data Gaps Requiring Resolution

The following critical data gaps were identified in this Evidence Pack:

| ID | Item | Severity | Impact | Remediation |
|----|------|----------|--------|-------------|
| DG001 | TFDA Package Insert Warnings/Contraindications | **Blocking** | Cannot enter S1 safety initial assessment | Download and parse package insert PDF from TFDA website |
| DG002 | Mechanism of Action (MOA) | **High** | Affects mechanism-relevance analysis | Query DrugBank API |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model has not produced any predicted new indications for ABACAVIR. Additionally, there are blocking-level data gaps (TFDA package insert warnings/contraindications) that prevent safety assessment. Without a prediction target and without baseline safety data, this candidate cannot proceed through the repurposing evaluation pipeline.

**To proceed, the following is needed:**
- Run or re-run TxGNN prediction pipeline for ABACAVIR (DB01048) to generate candidate indications
- Resolve DG001: Obtain TFDA package insert warnings and contraindications (Blocking)
- Resolve DG002: Retrieve detailed mechanism of action from DrugBank API
- Confirm Taiwan market availability or identify international sourcing pathways, as the drug is currently not marketed in Taiwan
- Once a predicted indication is available, collect clinical trial and literature evidence for the specific disease target
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

